Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G1B | P04054 | 1/20 | 0.59 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.59 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.56 |
| ▸ | S1PR2 | O95136 | 5/20 | 0.53 |
| ▸ | S1PR1 | P21453 | 5/20 | 0.53 |
| ▸ | S1PR3 | Q99500 | 5/20 | 0.53 |
| ▸ | S1PR4 | O95977 | 4/20 | 0.53 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | GMNN | O75496 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | THPO | P40225 | 1/20 | 0.43 |
| ▸ | MTOR | P42345 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28977213 | 1.00 | PLA2G1B (0.59) | PLA2G1BPLA2G2AOPRM1S1PR2S1PR1 | |
| SCHEMBL21161889 | 1.00 | PLA2G1B (0.59) | PLA2G1BPLA2G2AOPRM1S1PR2S1PR1 | |
| SCHEMBL15319803 | 1.00 | PLA2G1B (0.59) | PLA2G1BPLA2G2AOPRM1S1PR2S1PR1 | |
| SCHEMBL15054363 | 1.00 | PLA2G1B (0.59) | PLA2G1BPLA2G2AOPRM1S1PR2S1PR1 | |
| SCHEMBL18298232 | 1.00 | PLA2G1B (0.59) | PLA2G1BPLA2G2AOPRM1S1PR2S1PR1 | |
| SCHEMBL28446507 | 1.00 | PLA2G1B (0.59) | PLA2G1BPLA2G2AOPRM1S1PR2S1PR1 | |
| SCHEMBL21161890 | 0.95 | PLA2G1B (0.54) | PLA2G1BPLA2G2AOPRM1S1PR2S1PR1 | |
| SCHEMBL29186627 | 0.93 | PLA2G1B (0.57) | PLA2G1BPLA2G2AOPRM1S1PR2S1PR1 | |
| SCHEMBL6281344 | 0.93 | PLA2G1B (0.57) | PLA2G1BPLA2G2AOPRM1S1PR2S1PR1 | |
| SCHEMBL6279840 | 0.93 | PLA2G1B (0.57) | PLA2G1BPLA2G2AOPRM1S1PR2S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4637786-A2 | SMALL NUCLEAR RIBONUCLEOPROTEIN 13 POLYPEPTIDES, POLYNUCLEOTIDES, AND USES THEREOF | ModernaTX, Inc. (US) | 2025-10-29 | — | — | EP | disclosed |
| EP-4634388-A1 | COMPOSITIONS AND METHODS FOR INFECTIOUS DISEASES | Providence Therapeutics Holdings Inc. (CA) | 2025-10-22 | — | — | EP | disclosed |
| US-12403177-B2 | Silk-based product formulations and methods of use | COCOON BIOTECH INC. (US) | 2025-09-02 | — | — | US | disclosed |
| WO-2025061153-A1 | RNA-LIPID PARTICLES COMPRISING POLYSARCOSINE-LIPID CONJUGATE | Everest Medicines (China) Co., Ltd. (CN) | 2025-03-27 | — | — | WO | disclosed |
| EP-4522646-A2 | APOE LIPOPROTEIN SYSTEMS | Kisbee Therapeutics, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| EP-4452928-A1 | CONSTRAINED LIPIDS AND METHODS OF USE THEREOF | Renagade Therapeutics Management Inc. (US) | 2024-10-30 | — | — | EP | disclosed |
| EP-4402123-A1 | CYCLIC LIPIDS AND METHODS OF USE THEREOF | Renagade Therapeutics Management Inc. (US) | 2024-07-24 | — | — | EP | disclosed |
| WO-2024137953-A2 | SMALL NUCLEAR RIBONUCLEOPROTEIN 13 POLYPEPTIDES, POLYNUCLEOTIDES, AND USES THEREOF | MODERNATX, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| WO-2024026257-A2 | ENGINEERED POLYNUCLEOTIDES FOR CELL SELECTIVE EXPRESSION | MODERNATX, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| WO-2024026254-A1 | ENGINEERED POLYNUCLEOTIDES FOR TEMPORAL CONTROL OF EXPRESSION | MODERNATX, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| WO-2023023055-A1 | COMPOSITIONS AND METHODS FOR OPTIMIZING TROPISM OF DELIVERY SYSTEMS FOR RNA | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2023-02-23 | — | — | WO | disclosed |
| EP-3801625-A1 | SILK-BASED PRODUCT FORMULATIONS AND METHODS OF USE | Cocoon Biotech Inc. (US) | 2021-04-14 | — | — | EP | disclosed |
| US-10821175-B2 | Lipid nanoparticle vaccine adjuvants and antigen delivery systems | MERCK SHARP & DOHME CORP. (US) | 2020-11-03 | — | — | US | disclosed |
| EP-3365007-A2 | BROAD SPECTRUM INFLUENZA VIRUS VACCINE | ModernaTX, Inc. (US) | 2018-08-29 | — | — | EP | disclosed |
| WO-2017070620-A2 | BROAD SPECTRUM INFLUENZA VIRUS VACCINE | MODERNATX, INC. (US) | 2017-04-27 | — | — | WO | disclosed |
| US-20160361411-A1 | LIPID NANOPARTICLE VACCINE ADJUVANTS AND ANTIGEN DELIVERY SYSTEMS | MERCK SHARP & DOHME CORP (US) | 2016-12-15 | — | — | US | disclosed |
| EP-3076994-A2 | TARGETED ADAPTIVE VACCINES | Moderna Therapeutics, Inc. (US) | 2016-10-12 | — | — | EP | disclosed |
| EP-3019619-A2 | COMPOSITIONS COMPRISING SYNTHETIC POLYNUCLEOTIDES ENCODING CRISPR RELATED PROTEINS AND SYNTHETIC SGRNAS AND METHODS OF USE | Moderna Therapeutics, Inc. (US) | 2016-05-18 | — | — | EP | disclosed |
| WO-2015085318-A2 | TARGETED ADAPTIVE VACCINES | MODERNA THERAPEUTICS, INC. (US) | 2015-06-11 | — | — | WO | disclosed |
| WO-2015006747-A2 | COMPOSITIONS COMPRISING SYNTHETIC POLYNUCLEOTIDES ENCODING CRISPR RELATED PROTEINS AND SYNTHETIC SGRNAS AND METHODS OF USE. | MODERNA THERAPEUTICS, INC. (US) | 2015-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10821175-B2 | Lipid nanoparticle vaccine adjuvants and antigen delivery systems | TLR3, TLR5, TLR1 | PLA2G1B 176/4885PLA2G2A 101/4885OPRM1 3751/4885 |
| US-20160361411-A1 | LIPID NANOPARTICLE VACCINE ADJUVANTS AND ANTIGEN DELIVERY SYSTEMS | TLR3, TLR5, TLR1 | PLA2G1B 176/4885PLA2G2A 101/4885OPRM1 3751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.